Latest News on INVA

Financial News Based On Company


Advertisement
Advertisement

Innoviva gains new Overweight at Piper Sandler on diversified strategy

https://www.tradingview.com/news/seekingalpha:74f50052b094b:0-innoviva-gains-new-overweight-at-piper-sandler-on-diversified-strategy/
Innoviva (INVA) shares rose after Piper Sandler initiated coverage with an Overweight rating and a $29 price target, citing the company's unique diversified exposure to biopharma. Analyst David Amsellem highlighted Innoviva's royalty portfolio and hospital-focused brand name assets, which allow investors to benefit from FDA-approved treatments without typical development-stage risks. The company also holds strategic investments in development-stage biopharma firms, further adding to its value creation potential.

Piper Sandler initiates coverage of Innoviva at Overweight, sets price target at $29

https://www.tradingview.com/news/tradingview:98fe006f92eca:0-piper-sandler-initiates-coverage-of-innoviva-at-overweight-sets-price-target-at-29/
Piper Sandler has initiated coverage of Innoviva (INVA) with an Overweight rating and a price target of $29. This target implies a potential upside of 58.5% from the closing price of $18.30 on November 17. The article encourages readers to explore further analyst data and recommendations for Innoviva on TradingView.

Innoviva stock hits 52-week low at 18.6 USD

https://ng.investing.com/news/stock-market-news/innoviva-stock-hits-52week-low-at-186-usd-93CH-2811041
Innoviva Inc.'s stock has fallen to a 52-week low of 18.6 USD, reflecting a 14.93% decrease over the past year. Despite the downturn, InvestingPro analysis suggests the stock may be undervalued with a low P/E ratio of 7.37 and a PEG ratio of 0.1, indicating potential for recovery. The company's financial health is rated "GREAT" with a strong free cash flow yield, and analysts like Oppenheimer and Cantor Fitzgerald maintain outperform and overweight ratings, respectively, citing undervaluation and a positive business model transition.

Innoviva stock hits 52-week low at 18.6 USD

https://ca.investing.com/news/stock-market-news/innoviva-stock-hits-52week-low-at-186-usd-93CH-4961850
Innoviva Inc.'s stock has fallen to a 52-week low of 18.6 USD, representing a 14.93% decrease over the past year. Despite the downturn, InvestingPro analysis suggests the stock may be undervalued with a low P/E ratio of 7.37 and a strong free cash flow yield of 14%. The company is transitioning from a royalty-only business to a diversified biopharmaceutical firm, with analysts like Oppenheimer and Cantor Fitzgerald maintaining Outperform and Overweight ratings, respectively.

Innoviva (INVA) And The Question Hanging Over Its Latest Update

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/innoviva-inva-and-the-question-hanging-over-its-latest-updat
Innoviva (INVA) recently reported a significant shift from profit to loss in its third-quarter results, coinciding with a share price decline and the completion of a multi-year share repurchase program. Despite analysts deeming the stock 46% undervalued with a fair value of $35, the company faces challenges in executing its multi-pillar model, which relies on respiratory royalties, the Specialty Therapeutics business, and converting healthcare investments into durable cash flows. Investors are left to weigh whether the stock's slide is primarily due to business performance or an overswing in sentiment.
Advertisement

Impressive Earnings May Not Tell The Whole Story For Innoviva (NASDAQ:INVA)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/impressive-earnings-may-not-tell-the-whole-story-for-innoviv
Innoviva's recent strong earnings were dampened by an underlying factor: a US$42m gain attributed to unusual items. These one-off boosts often don't repeat, suggesting future profits might be weaker without significant business growth. While the company has shown impressive EPS growth over the last three years, the market seems cautious about the sustainability of its reported profit.

Innoviva stock hits 52-week low at 18.98 USD By Investing.com

https://ca.investing.com/news/stock-market-news/innoviva-stock-hits-52week-low-at-1898-usd-93CH-4943682
Innoviva Inc.'s stock has reached a 52-week low of $18.95, reflecting a significant decline over the past week and six months. Despite this, InvestingPro analysis suggests the stock is undervalued, trading at a low P/E ratio of 7.57 and a PEG ratio of 0.11, indicating potential for value investors. The company's recent Q2 revenue surpassed forecasts, and several analysts have maintained positive ratings, highlighting its transition to a diversified biopharma entity.

Innoviva, Inc. Stock 12‑Month Price Target Cut to $34.8, Implies 64% Upside

https://www.tradingview.com/news/tradingview:fc74a574e2e17:0-innoviva-inc-stock-12-month-price-target-cut-to-34-8-implies-64-upside/
Innoviva, Inc. (INVA) has seen its average 12-month price target cut slightly from $35 to $34.8 by 5 analysts, with individual forecasts ranging from $18 to $46 per share. This updated target suggests a potential upside of approximately 64% from its November 4th closing price. The consensus rating for INVA remains a "Buy," with 4 analysts recommending Buy and 1 recommending Sell.

Key facts: Innoviva Reports Q3 Results; NUZOLVENCE Launches in U.S.; Three Products Named Prix Galien Finalists

https://www.tradingview.com/news/tradingview:71f44a811d892:0-key-facts-innoviva-reports-q3-results-nuzolvence-launches-in-u-s-three-products-named-prix-galien-finalists/
Innoviva (INVA) reported Q3 2026 revenue of $106.1 million, a 1.6% decrease year-over-year, but U.S. product sales increased by 45%. The company launched its oral antibiotic NUZOLVENCE in the U.S. during Q3 and presented data for ZEVTERA and NUZOLVENCE at IDWeek 2026. XACDURO, ZEVTERA, and NUZOLVENCE were also recognized as finalists for the 2026 Prix Galien USA Best Pharmaceutical Product award, while analysts adjusted Innoviva's average 12-month price target to $34.80, maintaining a "Buy" consensus rating.

Innoviva (INVA) Tops Q3 Earnings Estimates

https://finance.yahoo.com/healthcare/articles/innoviva-inva-tops-q3-earnings-234513734.html
Innoviva (INVA) reported Q3 earnings of $0.5 per share, surpassing the Zacks Consensus Estimate of $0.49, marking a +2.04% surprise. However, the company's Q3 revenues of $106.12 million missed the consensus estimate by 6.89%. Despite recent underperformance compared to the S&P 500, Innoviva currently holds a Zacks Rank #3 (Hold), indicating an expectation of market-aligned performance in the near future.
Advertisement

Form 8K Innoviva Inc For: 4 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-innoviva-inc-for-4-november-93CH-4931835
This article announces the filing of a Form 8K by Innoviva Inc. on November 4th. The brief notice from Investing.com is minimal, simply stating the document's existence and date. It also links to Innoviva Inc.'s stock performance.

Form 8-K Innoviva, Inc. For: Nov 04

https://www.streetinsider.com/SEC+Filings/Form+8-K+Innoviva%2C+Inc.+For%3A+Nov+04/27290738.html
Innoviva, Inc. filed a Form 8-K on November 4, 2026, reporting its results of operations and financial condition for the quarter ended September 30, 2026. A press release detailing these results is furnished as Exhibit 99.1 to the report. The information is not considered "filed" for purposes of Section 18 of the Securities Exchange Act.

Innoviva Posts $73.9 Million Net Loss in Q3 2026 Amid Equity Investment Value Declines

https://kalkinemedia.com/us/news/announcements/innoviva-posts-739-million-net-loss-in-q3-2026-amid-equity-investment-value-declines
Innoviva, Inc. reported a net loss of $73.9 million in Q3 2026, primarily driven by negative fair value adjustments in its equity and equity method investments, despite an increase in gross profit and operating income. For the first nine months of 2026, the company still managed a net income of $29.3 million on total revenue of $323.7 million. Innoviva also repurchased $78.2 million of common stock during this period.

Trading Systems Reacting to (INVA) Volatility

https://news.stocktradersdaily.com/news_release/40/Trading_Systems_Reacting_to_INVA_Volatility_110226124402_1793598242.html
This article from Stock Traders Daily analyzes Innoviva Inc. (NASDAQ: INVA), noting a near-term strong sentiment influencing a neutral mid and long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional 26.8:1 risk-reward short setup. The piece outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for support and resistance levels.

Innoviva, Inc. (INVA) Stock forecasts

https://sg.finance.yahoo.com/research/reports/ARGUS_4747_QuantitativeReport_1793145600000
This article provides a brief overview of Innoviva Inc. (INVA), a company focused on healthcare assets. It highlights Argus's analysis of INVA, noting its current price at $21.22 and summarizing its business segments including a royalty portfolio and operating assets in critical care and infectious disease. The report also mentions related analyses for other companies.
Advertisement

Aurigene, Dr. Reddy’s, Innoviva Specialty Therapeutics and GARDP Recognized at CPHI

https://www.contractpharma.com/breaking-news/aurigene-dr-reddys-innoviva-specialty-therapeutics-and-gardp-recognized-at-cphi/
Aurigene Pharmaceutical Services Ltd., in collaboration with Dr. Reddy's Laboratories, Innoviva Specialty Therapeutics, and the Global Antibiotic Research & Development Partnership, received the CPHI Pharma Award 2026 in the True Partnership Excellence category. This award recognizes their joint efforts and integrated CRDMO model in addressing complex pharmaceutical development and manufacturing challenges for the Zoliflodacin Multiparty Partnership. Akhil Ravi, CEO of Aurigene, emphasized the importance of strong partnerships, technical excellence, and shared commitment to patients in advancing innovative medicines.

BlackRock reports its Innoviva (INVA) stake; an iShares fund has more than 5% interest.

https://www.stocktitan.net/sec-filings/INVA/schedule-13g-a-innoviva-inc-amended-passive-investment-disclosure-48b0a08da106.html
BlackRock, Inc. has reported a beneficial ownership of 11,138,961 common shares in Innoviva, Inc. (INVA), representing 15.4% of the class as of September 30, 2026. The filing indicates BlackRock holds sole voting power over 10,924,497 shares and sole dispositive power over all 11,138,961 shares. Additionally, the iShares Core S&P Small-Cap ETF is identified as having an interest exceeding 5% in Innoviva's outstanding common stock.

Innoviva, Inc. Estimates – NASDAQ:INVA

https://www.tradingview.com/symbols/NASDAQ-INVA/financials-estimates/
This article provides an overview of Innoviva, Inc. (NASDAQ: INVA) financial data and analyst estimates available on TradingView. It highlights sections for exploring reported financial data, comparing actual results with estimates, and visualizing trends across income statements, balance sheets, cash flow statements, and valuation metrics. The content emphasizes that it is not investment advice and encourages users to conduct their own research.

Innoviva, Inc. (INVA) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_4747_QuantitativeReport_1791936000000
This article provides a brief overview of Innoviva Inc. (INVA), a company focused on healthcare assets, including a royalty portfolio, critical care, and infectious disease operating assets. It highlights an Argus research report from October 14, 2026, which includes a current price of $21.06 and a price target for INVA. The report's full details are available to premium subscribers.

Enterprise value to EBITDA forward of Innoviva, Inc. – NASDAQ:INVA

https://www.tradingview.com/symbols/NASDAQ-INVA/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/
This article provides the enterprise value to EBITDA forward for Innoviva, Inc. (NASDAQ: INVA). It displays the period, value, change, and percentage change for this financial metric. The content is primarily a data point from TradingView, which sources its market and reference data from ICE Data Services and FactSet, respectively.
Advertisement

Does Unusual Options Trading Change The Bull Case For Innoviva Stock (INVA)?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/does-unusual-options-trading-change-the-bull-case-for-innovi
Unusual options trading in Innoviva (INVA) stock, specifically heavy activity in its December 2026 US$10.00 call options, suggests derivatives traders are anticipating a major development not yet public. While Innoviva's core strategy relies on respiratory royalties, specialty therapeutics, and equity stakes, with a key focus on the NUZOLVENCE launch, analysts forecast declining earnings despite revenue growth. The options activity indicates market participants are stress-testing the gap between the company's growth narrative and analysts' more conservative financial projections, especially concerning the NUZOLVENCE rollout and existing revenue streams.

Does Unusual Options Trading Change The Bull Case For Innoviva Stock (INVA)?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/does-unusual-options-trading-change-the-bull-case-for-innovi/amp
Heavy trading in Innoviva's Dec. 18, 2026 US$10.00 call options has raised questions about the stock's bull case, signaling potential major developments not yet public. Analysts project a decline in Innoviva's earnings by 2029 despite revenue growth, with a consensus price target of US$35.00 against a current share price of US$21.14. This options activity encourages investors to re-evaluate their expectations for the NUZOLVENCE rollout and other key growth drivers against the implied financial trajectory.

Innoviva, Inc. (INVA) Stock Forecasts

https://finance.yahoo.com/research/reports/ARGUS_4747_QuantitativeReport_1791936000000
This article provides a stock forecast for Innoviva, Inc. (INVA) based on an Argus research report from October 14, 2026. Innoviva is described as a company with a portfolio of royalties healthcare assets, including a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. The report offers a current price of $20.86 and suggests upgrading for more detailed research and insights.

Do Options Traders Know Something About Innoviva Stock We Don't?

https://fr.tradingview.com/news/zacks:b6a18112e094b:0-do-options-traders-know-something-about-innoviva-stock-we-don-t/
Options traders are showing significant interest in Innoviva, Inc. (INVA) with high implied volatility for a Dec. 18, 2026 $10.00 Call, suggesting expectations of a major price movement. Despite this, analysts currently rate Innoviva as a Zacks Rank #3 (Hold), with recent consensus estimates for the current quarter slightly decreasing. This divergence could indicate a developing trade, potentially where seasoned options traders sell premium betting the stock won't move as much as implied.

Precision Trading with Innoviva Inc. (INVA) Risk Zones

https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Innoviva_Inc._INVA_Risk_Zones_101226032601_1791833161.html
The article details precision trading strategies for Innoviva Inc. (INVA), highlighting a 30.7:1 risk-reward setup targeting an 8.9% gain with only 0.3% risk. It provides institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for different risk profiles and holding periods.
Advertisement

Do Options Traders Know Something About Innoviva Stock We Don't?

https://www.tradingview.com/news/zacks:b6a18112e094b:0-do-options-traders-know-something-about-innoviva-stock-we-don-t/
Options traders are showing significant interest in Innoviva, Inc. (INVA) stock, with high implied volatility for a December 2026 call option suggesting expectations of a major price movement. While analysts currently rate Innoviva as a Zacks Rank #3 (Hold) in a low-ranking industry, the implied volatility could indicate a potential trading opportunity, possibly for selling premium.

Enterprise value to EBITDA forward of Innoviva, Inc. – BX:HVE

https://www.tradingview.com/symbols/BX-HVE/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/
This article provides financial information for Innoviva, Inc. (BX:HVE), specifically focusing on its enterprise value to EBITDA forward metric. The data is presented within the TradingView platform, noting that the market was closed at the time of access and no trades were recorded.

Innoviva, Inc. (INVA) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_4747_QuantitativeReport_1791331200000
This article provides stock forecast information for Innoviva, Inc. (INVA), a company with a portfolio of royalties healthcare assets. An Argus report from October 7, 2026, is highlighted, noting a current price of $21.21 and encouraging an upgrade for full access to premium research. The article also lists related analyst reports for other companies.

Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?

https://finance.yahoo.com/markets/stocks/articles/innoviva-inva-undervalued-zacks-flags-191909404.html
Zacks has identified Innoviva (INVA) as a strong value pick due to its A grade for Value and favorable P/E and cash flow metrics, despite mixed recent trading performance. The stock is considered 40% undervalued with a fair value of $35 per share, largely based on expected respiratory royalties and the potential contributions from Armata Pharmaceuticals and Nortiva Bio. Investors are encouraged to weigh both the bullish narrative, supported by long-term returns and future prospects, against risks like a recent net income decline.

Should Value Investors Buy Innoviva (INVA) Stock?

https://sg.finance.yahoo.com/news/value-investors-buy-innoviva-inva-124004586.html
The article analyzes Innoviva (INVA) stock from a value investing perspective, noting its strong Zacks Rank #2 (Buy) and an "A" grade for Value. It highlights key valuation metrics such as a low P/E ratio (10.12 vs. industry average 17.64), a favorable P/S ratio (3.46 vs. industry average 4.23), and an attractive P/CF ratio (20.06 vs. industry average 29.69). Based on these metrics and a strong earnings outlook, the article concludes that INVA appears to be an undervalued stock.
Advertisement

Precision Trading with Innoviva Inc. (INVA) Risk Zones

https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Innoviva_Inc._INVA_Risk_Zones_100226090402_1790946242.html
This article provides a detailed analysis of Innoviva Inc. (INVA) stock, identifying key findings such as strong near-term sentiment and elevated downside risk. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, alongside a multi-timeframe signal analysis. The report aims to help traders optimize position sizing and manage drawdown risk through precision trading.

Innoviva, Inc. (INVA) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/INVA/
This article provides comprehensive financial information for Innoviva, Inc. (INVA), including its current stock price, recent performance metrics, key financial data, and analyst insights. It details the company's biopharmaceutical operations, royalty portfolio, and strategic partnerships, alongside performance comparisons to the S&P 500.

THRX5561968 Bond Profile: Coupon and Redemption

https://www.tradingview.com/symbols/FINRA-THRX5561968/profile/
This article provides a detailed profile of the Innoviva, Inc. 2.125% 15-MAR-2028 corporate bond (THRX5561968). It covers key facts about the issuer and the bond, including its maturity date, face value, and semi-annual fixed-rate coupon payments. The bond's upcoming payout schedule and redemption information are also highlighted, offering a comprehensive overview for potential investors.

Innoviva Number of Employees 2026 | Employee Count & Headcount Data

https://www.reveliolabs.com/companies/innoviva/employees
Innoviva, Inc. (NASDAQ: INVA) had approximately 184 employees worldwide as of March 2026, representing a 33.5% growth from 2023. The company is actively hiring, with 7 job postings in 2026, and its workforce is concentrated in North America, with an average salary of $150,416. Employee sentiment is negative but shows improvement.

Price to sales forward of Innoviva, Inc. – NASDAQ:INVA

https://www.tradingview.com/symbols/NASDAQ-INVA/financials-statistics-and-ratios/price-sales-fwd/
This article provides financial information for Innoviva, Inc. (NASDAQ: INVA), specifically focusing on its forward price-to-sales ratio. It presents a simple data point without further analysis or commentary, embedded within a larger financial platform's interface.
Advertisement

Innoviva at Cantor conference: growth bets beyond COPD royalties

https://www.investing.com/news/transcripts/innoviva-at-cantor-conference-growth-bets-beyond-copd-royalties-93CH-4895918
Innoviva presented at the Cantor Fitzgerald Global Healthcare Conference, outlining a strategy built on existing COPD royalty streams, a growing specialty therapeutics unit, and a new investment in oral drug-delivery technology via its Nortiva subsidiary. The company expects over $1 billion in COPD royalty revenue in the next five years, which will fund the expansion of its specialty therapeutics business and strategic investments like the LYNX platform, aiming to diversify its revenue streams beyond the eventual expiration of its legacy royalties. Innoviva's management emphasized balancing reinvestment, strategic acquisitions, and share buybacks to maximize shareholder value.

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

https://www.biospace.com/press-releases/innoviva-specialty-therapeutics-antimicrobial-therapies-xacduro-zevtera-and-nuzolvence-designated-finalists-for-the-2026-prix-galien-usa-best-pharmaceutical-product-award
Innoviva Specialty Therapeutics has announced that three of its antimicrobial therapies, XACDURO®, ZEVTERA®, and NUZOLVENCE®, have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This is the third consecutive year an Innoviva product has been recognized, highlighting the clinical significance of its portfolio in combating drug-resistant infections. The award, often called the "Nobel Prize of the pharmaceutical industry," acknowledges significant advancements that improve human health, with winners to be announced on October 29, 2026.

Innoviva to Participate in Upcoming September 2026 Investor Conferences

https://www.biospace.com/press-releases/innoviva-to-participate-in-upcoming-september-2026-investor-conferences
Innoviva, Inc. (NASDAQ: INVA) announced its participation in four investor conferences in September 2026: Citi's Biopharma Back to School Conference, Cantor Global Healthcare Conference, H.C. Wainwright 28th Annual Global Investment Conference, and Morgan Stanley 24th Annual Global Healthcare Conference. Management will engage in one-on-one meetings, a fireside chat, and a presentation. Webcasts of presentations will be available on Innoviva's investor relations website.

Innoviva (NASDAQ: INVA) CFO now holds 88,013 shares after tax withholding

https://www.stocktitan.net/sec-filings/INVA/form-4-innoviva-inc-insider-trading-activity-67d8ecb90f0b.html
Innoviva's CFO, Stephen Basso, now holds 88,013 shares of common stock after 558 shares were withheld for income tax obligations related to the quarterly vesting of employee equity awards. The shares were disposed of at $21.00 each on August 20, 2026, as detailed in a Form 4 SEC filing. This transaction was not an open-market sale but a tax-related withholding.

Innoviva (NASDAQ: INVA) CEO sees 1,130 shares withheld for taxes

https://www.stocktitan.net/sec-filings/INVA/form-4-innoviva-inc-insider-trading-activity-43c43bce229b.html
Innoviva, Inc. (NASDAQ: INVA) CEO Pavel Raifeld had 1,130 shares of common stock withheld on August 20, 2026, to cover income tax withholding obligations from vested equity awards. This transaction, reported on a Form 4 filing, involved shares valued at $21.00 each. Following this disposition, Raifeld directly owns 284,799 Innoviva common shares.
Advertisement

Innoviva CEO Pavel Raifeld Executes Tax-Related Share Withholding Transaction

https://kalkinemedia.com/us/news/announcements/innoviva-ceo-pavel-raifeld-executes-tax-related-share-withholding-transaction
Innoviva CEO and Director Pavel Raifeld executed a tax-related share withholding transaction on August 20, 2026. This involved the disposition of 1,130 shares of common stock at $21 per share to cover income tax obligations from vested employee equity awards. Following this transaction, Raifeld directly beneficially owns 284,799 shares of Innoviva, Inc. common stock.

Cantor Fitzgerald reiterates Innoviva stock rating at overweight

https://m.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-innoviva-stock-rating-at-overweight-93CH-4871734?ampMode=1
Cantor Fitzgerald has reiterated an overweight rating for Innoviva Technology, Inc. with a $34 price target, noting the company's successful evolution into a diversified biopharma with strong commercial growth and strategic healthcare assets. Innoviva shows profitable growth with a 50%+ CAGR, an undervalued stock based on a low P/E ratio and InvestingPro analysis, and a strong balance sheet with more cash than debt. Recent developments include exceeding revenue forecasts, launching a new subsidiary for drug delivery, and securing international distribution agreements.

NewEdge Wealth LLC Acquires New Stake in Innoviva, Inc. $INVA

https://www.marketbeat.com/instant-alerts/filing-newedge-wealth-llc-acquires-new-stake-in-innoviva-inc-inva-2026-08-21/
NewEdge Wealth LLC has acquired a new stake in Innoviva, Inc. (NASDAQ:INVA) during the second quarter, purchasing 99,367 shares valued at approximately $2.26 million. This move makes NewEdge Wealth LLC own about 0.13% of the biotechnology company, while institutional investors collectively hold 99.12% of Innoviva. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $34.75, despite the company's shares opening at $21.00 with a market capitalization of $1.52 billion.

Innoviva, Inc. (NASDAQ:INVA) Receives Average Rating of "Hold" from Brokerages

https://www.marketbeat.com/instant-alerts/innoviva-inc-nasdaqinva-receives-average-rating-of-hold-from-brokerages-2026-08-21/
Innoviva, Inc. (NASDAQ:INVA) has received an average rating of "Hold" from brokerage firms, with six ratings contributing to this consensus. The company's stock opened at $21.00, has a market cap of $1.52 billion, and a P/E ratio of 5.12. Several institutional investors have recently adjusted their holdings in Innoviva, and the company focuses on acquiring and monetizing royalty and license interests in biopharmaceutical products, particularly inhaled respiratory therapies.

ETFs Investing in Innoviva, Inc. Stocks

https://www.tradingview.com/symbols/MUN-HVE/etfs/
This article lists various ETFs that include Innoviva, Inc. (HVE) stocks in their holdings. The ETFs are primarily focused on small-cap, value, and healthcare sectors, providing investors with diversified options to gain exposure to Innoviva, Inc. The data includes market value, weight of Innoviva in the ETF, issuer, management style, expense ratio, and performance metrics for each fund.
Advertisement

70,000 Shares in Innoviva, Inc. $INVA Purchased by Chase Investment Counsel Corp

https://www.marketbeat.com/instant-alerts/filing-70000-shares-in-innoviva-inc-inva-purchased-by-chase-investment-counsel-corp-2026-08-17/
Chase Investment Counsel Corp has acquired 70,000 shares of Innoviva, Inc. (NASDAQ:INVA) for approximately $1.59 million, representing a new stake of about 0.09% in the company. Institutional ownership in Innoviva remains high at 99.12%, with firms like Vanguard Group and Arrowstreet Capital also increasing their positions. Innoviva has a "Hold" consensus rating from analysts with an average price target of $34.75, despite mixed recent recommendations and a current trading price of around $21.19.

Innoviva’s Earnings Swing And Buyback Might Change The Case For Investing In Innoviva (INVA)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/innovivas-earnings-swing-and-buyback-might-change-the-case-f/amp
Innoviva (INVA) reported mixed Q2 2026 results with increased revenue but a net loss, contrasting with positive six-month figures. The company also completed a share buyback, signaling a focus on capital returns despite short-term earnings volatility. Investors are encouraged to consider long-term profitability and the impact of the buyback against recent index removals.

Innoviva’s Earnings Swing And Buyback Might Change The Case For Investing In Innoviva (INVA)

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-inva/innoviva/news/innovivas-earnings-swing-and-buyback-might-change-the-case-f
Innoviva (INVA) recently reported a Q2 2026 net loss of US$83.42 million despite increased revenue, alongside completing a US$66.40 million share buyback. While the quarterly loss introduces volatility, the company's six-month figures show overall revenue and net income growth, suggesting a complex investment narrative involving historical profitability, low earnings multiples, and capital returns. The article suggests investors consider these factors along with differing fair value estimates and potential risks related to earnings quality.

Bank of America Corp DE Has $37.75 Million Stake in Innoviva, Inc. $INVA

https://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-has-3775-million-stake-in-innoviva-inc-inva-2026-08-14/
Bank of America Corp DE increased its stake in Innoviva, Inc. (NASDAQ:INVA) by 6.6% in the first quarter, now owning 1,619,994 shares valued at approximately $37.75 million. Institutional investors and hedge funds collectively own 99.12% of Innoviva, and the stock currently has an average "Hold" rating from analysts with an average target price of $34.75. Innoviva is a royalty-focused life sciences company specializing in biopharmaceutical products, particularly inhaled respiratory therapies.

Three Innoviva therapies named finalists for Prix Galien award

https://www.investing.com/news/company-news/three-innoviva-therapies-named-finalists-for-prix-galien-award-93CH-4852584
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., announced that three of its infectious disease therapies—XACDURO, ZEVTERA, and NUZOLVENCE—have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva product has been recognized, highlighting advancements in treatments for severe bacterial infections and drug-resistant gonorrhea. The winners will be announced on October 29, 2026.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement